CKS2 | OmnibusX

I. Expression across cell types

Name	Number of supported studies	Average coverage
B cell	21 studies	30% ± 11%	Explore
conventional dendritic cell	18 studies	28% ± 11%	Explore
T cell	16 studies	31% ± 12%	Explore
natural killer cell	11 studies	29% ± 8%	Explore
endothelial cell	11 studies	25% ± 6%	Explore
macrophage	11 studies	29% ± 10%	Explore
CD8-positive, alpha-beta T cell	11 studies	38% ± 16%	Explore
fibroblast	9 studies	22% ± 4%	Explore
CD4-positive, alpha-beta T cell	9 studies	41% ± 19%	Explore
epithelial cell	9 studies	43% ± 22%	Explore
progenitor cell	8 studies	33% ± 11%	Explore
connective tissue cell	8 studies	22% ± 9%	Explore
memory B cell	8 studies	24% ± 7%	Explore
dendritic cell	7 studies	26% ± 13%	Explore
plasmablast	7 studies	40% ± 18%	Explore
monocyte	7 studies	23% ± 5%	Explore
smooth muscle cell	7 studies	20% ± 2%	Explore
mast cell	7 studies	27% ± 11%	Explore
regulatory T cell	7 studies	28% ± 9%	Explore
plasmacytoid dendritic cell	7 studies	28% ± 10%	Explore
pericyte	6 studies	23% ± 10%	Explore
naive B cell	6 studies	21% ± 9%	Explore
abnormal cell	6 studies	26% ± 5%	Explore
precursor B cell	6 studies	43% ± 22%	Explore
myeloid cell	6 studies	25% ± 9%	Explore
basal cell	6 studies	22% ± 4%	Explore
erythrocyte	6 studies	42% ± 21%	Explore
gamma-delta T cell	6 studies	26% ± 14%	Explore
hematopoietic precursor cell	5 studies	37% ± 12%	Explore
leukocyte	5 studies	37% ± 13%	Explore
transit amplifying cell	5 studies	36% ± 9%	Explore
pro-B cell	5 studies	37% ± 13%	Explore
plasma cell	5 studies	37% ± 9%	Explore
type II pneumocyte	5 studies	32% ± 15%	Explore
mononuclear phagocyte	4 studies	28% ± 8%	Explore
classical monocyte	4 studies	20% ± 4%	Explore
goblet cell	4 studies	24% ± 9%	Explore
erythroblast	4 studies	64% ± 20%	Explore
hematopoietic stem cell	4 studies	27% ± 6%	Explore
germinal center B cell	4 studies	30% ± 8%	Explore
effector CD8-positive, alpha-beta T cell	4 studies	31% ± 10%	Explore
CD8-positive, alpha-beta memory T cell	4 studies	22% ± 4%	Explore
CD4-positive, alpha-beta memory T cell	4 studies	22% ± 6%	Explore
deuterosomal cell	3 studies	28% ± 5%	Explore
epithelial cell of proximal tubule	3 studies	23% ± 4%	Explore
neural crest cell	3 studies	44% ± 18%	Explore
innate lymphoid cell	3 studies	21% ± 3%	Explore
CD16-negative, CD56-bright natural killer cell, human	3 studies	23% ± 7%	Explore
immature B cell	3 studies	30% ± 4%	Explore
non-classical monocyte	3 studies	16% ± 1%	Explore
ciliated cell	3 studies	36% ± 16%	Explore
effector CD4-positive, alpha-beta T cell	3 studies	22% ± 5%	Explore
megakaryocyte-erythroid progenitor cell	3 studies	57% ± 18%	Explore
enteroendocrine cell	3 studies	18% ± 2%	Explore
mature NK T cell	3 studies	21% ± 2%	Explore

II. Expression across tissues

Name	Number of supported studies	Average coverage
kidney	7 studies	24% ± 6%	Explore
lung	6 studies	25% ± 5%	Explore
intestine	4 studies	25% ± 5%	Explore
bone marrow	4 studies	20% ± 3%	Explore
uterus	3 studies	27% ± 14%	Explore
adrenal gland	3 studies	25% ± 0%	Explore
liver	3 studies	45% ± 23%	Explore
skin	3 studies	26% ± 3%	Explore
thymus	3 studies	40% ± 11%	Explore

Tissue	GTEx Coverage	GTEx Average TPM	GTEx Number of samples	TCGA Coverage	TCGA Average TPM	TCGA Number of samples
lung	98%	566.77	564 / 578	96%	199.29	1111 / 1155
skin	96%	1337.71	1739 / 1809	97%	186.87	458 / 472
bladder	86%	251.95	18 / 21	99%	263.02	497 / 504
adrenal gland	100%	1274.25	258 / 258	82%	164.25	188 / 230
ovary	80%	178.36	144 / 180	100%	341.19	430 / 430
intestine	81%	404.21	779 / 966	99%	296.81	520 / 527
stomach	79%	288.31	284 / 359	100%	279.54	285 / 286
breast	79%	172.51	363 / 459	97%	199.26	1090 / 1118
prostate	91%	251.77	224 / 245	76%	64.99	383 / 502
esophagus	67%	419.84	971 / 1445	98%	243.75	180 / 183
uterus	65%	125.96	110 / 170	100%	326.05	458 / 459
thymus	74%	151.27	483 / 653	86%	114.08	520 / 605
liver	91%	314.96	205 / 226	68%	78.05	276 / 406
kidney	100%	619.06	89 / 89	50%	44.14	450 / 901
brain	68%	150.98	1798 / 2642	55%	79.85	390 / 705
lymph node	0%	0	0 / 0	100%	471.84	29 / 29
spleen	100%	688.39	241 / 241	0%	0	0 / 0
tonsil	0%	0	0 / 0	100%	305.93	45 / 45
ureter	0%	0	0 / 0	100%	136.08	1 / 1
pancreas	12%	17.60	38 / 328	85%	102.04	151 / 178
adipose	80%	188.56	963 / 1204	0%	0	0 / 0
peripheral blood	77%	1567.69	717 / 929	0%	0	0 / 0
eye	0%	0	0 / 0	61%	61.22	49 / 80
heart	60%	106.81	517 / 861	0%	0	0 / 0
blood vessel	55%	97.70	739 / 1335	0%	0	0 / 0
muscle	50%	93.82	399 / 803	0%	0	0 / 0
abdomen	0%	0	0 / 0	0%	0	0 / 0
bone marrow	0%	0	0 / 0	0%	0	0 / 0
diaphragm	0%	0	0 / 0	0%	0	0 / 0
gingiva	0%	0	0 / 0	0%	0	0 / 0
nasal cavity	0%	0	0 / 0	0%	0	0 / 0
nasopharynx	0%	0	0 / 0	0%	0	0 / 0
nose	0%	0	0 / 0	0%	0	0 / 0
placenta	0%	0	0 / 0	0%	0	0 / 0
spinal column	0%	0	0 / 0	0%	0	0 / 0

III. Associated gene sets

GO_0051301	Biological process	cell division
GO_0007127	Biological process	meiosis I
GO_0007346	Biological process	regulation of mitotic cell cycle
GO_0048144	Biological process	fibroblast proliferation
GO_0044772	Biological process	mitotic cell cycle phase transition
GO_0006357	Biological process	regulation of transcription by RNA polymerase II
GO_0019005	Cellular component	SCF ubiquitin ligase complex
GO_0000307	Cellular component	cyclin-dependent protein kinase holoenzyme complex
GO_0061575	Molecular function	cyclin-dependent protein serine/threonine kinase activator activity
GO_0043130	Molecular function	ubiquitin binding
GO_0019901	Molecular function	protein kinase binding
GO_0005515	Molecular function	protein binding
GO_0042393	Molecular function	histone binding
GO_0003682	Molecular function	chromatin binding

IV. Literature review

[source]

Gene name	CKS2
Protein name	Cyclin-dependent kinases regulatory subunit 2 (CKS-2)
Synonyms
Description	FUNCTION: Binds to the catalytic subunit of the cyclin dependent kinases and is essential for their biological function.
Accessions	P33552 ENST00000314355.7

CKS2 report

I. Expression across cell types

II. Expression across tissues

III. Associated gene sets

IV. Literature review